<DOC>
	<DOCNO>NCT02622477</DOCNO>
	<brief_summary>The purpose study assess clinical outcome patient mild moderate IPF one-year therapy Esbriet® ( Pirfenidone ) .</brief_summary>
	<brief_title>Clinical Progression Mild Moderate Idiopathic Pulmonary Fibrosis ( IPF ) Under Therapy With Esbriet® ( Pirfenidone )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Adult patient confident diagnosis mild moderate IPF , previously yet treat Pirfenidone Hypersensitivity active substance one excipients Pirfenidone Concomitant use Fluvoxamin Severe hepatic impairment end stage liver disease Severe renal impairment ( CreatinineClearance &lt; 30 ml/min ) end stage renal disease require dialysis Simultaneous participation interventional study Previously treat Pirfenidone longer 30 day</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>